Yesterday, Dec. 16, 2015, 113 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $10.88 to $18,402,925.00.

Highlighted Stocks Traded by Insiders:

Cambrex (CBM) - FREE Research Report

Hendrix Leon J Jr, who is Director at Cambrex, sold 7,000 shares at $51.34 on Dec. 16, 2015. Following this transaction, the Director owned 71,211 shares meaning that the stake was reduced by 8.95% with the 7,000-share transaction.

The shares most recently traded at $52.00, up $0.66, or 1.26% since the insider transaction. Historical insider transactions for Cambrex go as follows:

  • 4-Week # shares sold: 83,551
  • 12-Week # shares sold: 93,551
  • 24-Week # shares sold: 99,507

The average volume for Cambrex has been 440,900 shares per day over the past 30 days. Cambrex has a market cap of $1.6 billion and is part of the health care sector and drugs industry. Shares are up 137.97% year-to-date as of the close of trading on Wednesday.

Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. The company has a P/E ratio of 24.7. Currently, there is 1 analyst who rates Cambrex a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on CBM - FREE

TheStreet Quant Ratings

rates Cambrex as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, impressive record of earnings per share growth, compelling growth in net income and notable return on equity. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full

Cambrex Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

EMC Insurance Group (EMCI) - FREE Research Report

Lovell Michael Alan, who is Senior Vice President at EMC Insurance Group, sold 563 shares at $25.67 on Dec. 16, 2015. Following this transaction, the Senior Vice President owned 6,422 shares meaning that the stake was reduced by 8.06% with the 563-share transaction.

The shares most recently traded at $26.53, up $0.86, or 3.25% since the insider transaction. Historical insider transactions for EMC Insurance Group go as follows:

  • 4-Week # shares sold: 930
  • 12-Week # shares sold: 930
  • 24-Week # shares sold: 930

The average volume for EMC Insurance Group has been 22,300 shares per day over the past 30 days. EMC Insurance Group has a market cap of $538.2 million and is part of the financial sector and insurance industry. Shares are up 12.52% year-to-date as of the close of trading on Wednesday.

EMC Insurance Group Inc., an insurance holding company, provides property and casualty insurance, and reinsurance products in the United States. It operates through two segments, Property and Casualty Insurance, and Reinsurance. The stock currently has a dividend yield of 2.93%. The company has a P/E ratio of 9.4. Currently, there is 1 analyst who rates EMC Insurance Group a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on EMCI - FREE

TheStreet Recommends

TheStreet Quant Ratings

rates EMC Insurance Group as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, attractive valuation levels and good cash flow from operations. We feel its strengths outweigh the fact that the company shows low profit margins. Get the full

EMC Insurance Group Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Prospect Capital (PSEC) - FREE Research Report

Oswald Brian H, who is CFO, CCO, Treasury & Secretary at Prospect Capital, bought 10,000 shares at $6.30 on Dec. 16, 2015. Following this transaction, the CFO, CCO, Treasury & Secretary owned 475,000 shares meaning that the stake was boosted by 2.15% with the 10,000-share transaction.

Eliasek M Grier, who is Chief Operating Officer at Prospect Capital, bought 20,000 shares at $6.28 on Dec. 16, 2015. Following this transaction, the Chief Operating Officer owned 372,196 shares meaning that the stake was boosted by 5.68% with the 20,000-share transaction.

Barry John F, who is Chief Executive Officer at Prospect Capital, bought 487,500 shares at $6.32 on Dec. 16, 2015. Following this transaction, the Chief Executive Officer owned 6.4 million shares meaning that the stake was boosted by 8.21% with the 487,500-share transaction.

The shares most recently traded at $6.79, up $0.47, or 6.89% since the insider transaction. Historical insider transactions for Prospect Capital go as follows:

  • 4-Week # shares bought: 360,000
  • 12-Week # shares bought: 361,000
  • 24-Week # shares bought: 362,000

The average volume for Prospect Capital has been 2.7 million shares per day over the past 30 days. Prospect Capital has a market cap of $2.3 billion and is part of the financial sector and financial services industry. Shares are down 19.61% year-to-date as of the close of trading on Wednesday.

Prospect Capital Corporation is a business development company. The stock currently has a dividend yield of 15.55%. The company has a P/E ratio of 6.5. Currently, there are 3 analysts who rate Prospect Capital a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on PSEC - FREE

TheStreet Quant Ratings

rates Prospect Capital as a

hold

. The company's strengths can be seen in multiple areas, such as its good cash flow from operations and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and a generally disappointing performance in the stock itself. Get the full

Prospect Capital Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.